Prosecution Insights
Last updated: October 25, 2026
Application No. 19/429,715

PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF

Non-Final OA §112
Filed
Dec 22, 2025
Priority
Oct 20, 2022 — provisional 63/417,896 +4 more
Examiner
SHIM, DAVID M.
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Transcend Therapeutics Inc.
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
2y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
57 granted / 97 resolved
-1.2% vs TC avg
Strong +58% interview lift
Without
With
+58.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
142
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
14.1%
-25.9% vs TC avg
§112
36.0%
-4.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 97 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-18 are pending in the application. Claim 7 is rejected. Claim 1 is objected to. Claim 2-6 and 8-11 are allowed. Claims 12-18 are withdrawn. Restriction/Election of Species Applicant’s election without traverse of Group I, claims 1-11, in the reply filed on July 2, 2026 is acknowledged. Claims 12-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on July 2, 2026. Priority This application is labeled as a divisional of U.S. Application No. 18/672,696, filed on May 23, 2024, which is a continuation of U.S. Application No. PCT/US23/35399, filed on October 18, 2023, which claims benefit of Provisional Application No. 63/471,432, filed on June 6, 2023, which claims benefit of Provisional Application No. 63/437,288, filed on January 5, 2023, which claims benefit of Provisional Application No. 63/417,896, filed on October 20, 2022. Information Disclosure Statement The Information Disclosure Statement(s) (IDS) filed on January 2, 2026 is in compliance with the provisions of 37 CFR 1.97 and 1.98. Accordingly, the Examiner has considered the IDS documents and signed copies of the 1449 forms are attached. Claim Objections Claim 1 is objected to because of the following informalities: Claim 1 should be amended to recite in step (ii): “obtaining a solution of the MDPBP from (i) in methyl isobutyl ketone...” for sake of clarity and consistency. Appropriate correction is required. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. § 112(d): (d) REFERENCE IN DEPENDENT FORMS — Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. § 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 7 is rejected under 35 U.S.C. § 112(d) or pre-AIA 35 U.S.C. § 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 7 recites the limitation “wherein said temperature is 0-10°C.” With respect to numerical values and ranges, the instant specification discloses the following in paragraph [0126]: PNG media_image1.png 107 926 media_image1.png Greyscale PNG media_image2.png 85 927 media_image2.png Greyscale Accordingly, a temperature range of “0-10°C” as recited in claim 7 is being interpreted as including a temperature value of 10°C. Consequently, claim 7 is drawn towards a temperature value of 10°C and is, therefore, broader in scope than parent claim 6 which only provides for temperature values “below 10°C.” Consequently, claim 7 fails to further limit the subject matter of parent claim 6. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1-11 are free of the prior art. Claim 2-6 and 8-11 are allowed. Claims 1 and 7 are otherwise allowable if amended to address the issues described above. Conclusion Claim 2-6 and 8-11 are allowed. Claim 1 is objected to. Claim 7 is rejected. Claims 12-18 are withdrawn. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID SHIM whose telephone number is (571)270-1205. The examiner can normally be reached Monday - Friday, 9 AM - 5 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, RENEE CLAYTOR can be reached at (571)272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.M.S./Examiner, Art Unit 1626 /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Dec 22, 2025
Application Filed
Sep 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758527
ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS
2y 1m to grant Granted Oct 13, 2026
Patent 12746238
SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9
2y 6m to grant Granted Sep 29, 2026
Patent 12698284
SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE
2y 11m to grant Granted Aug 04, 2026
Patent 12686676
COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION
2y 7m to grant Granted Jul 21, 2026
Patent 12673056
ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD
3y 7m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+58.5%)
2y 11m (~2y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 97 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month